Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Operator Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results conference call. At this time, all lines are in listen-only mode.

Celex Oncology’s first attendance at Bio-Europe Spring 2025 follows their recent win at the 2024 EIT Health Catapult ...

Discover a study that compared the effectiveness of P043 versus omalizumab in managing uncontrolled allergic asthma.

Q4 2024 Earnings Call Transcript March 11, 2025 Operator: Welcome to the SIGA Business Update Call. Before we turn the call ...

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

Upstream is developing verekitug, the only monoclonal antibody currently in clinical development ... supporting our strategy of leveraging verekitug's unique mechanism of action to improve treatment ...

BEIJING, March 4 (Xinhua) -- China has initiated legal action against the United States under the World Trade Organization (WTO) dispute settlement mechanism regarding the latter's latest tariff ...

This naturally occurring antibody—which was discovered 40 years ago at Osaka University in Japan—can recognize IZUMO1 and disrupt fertilization. But until now, the specifics of this mechanism ...

The acquired knowledge is a vital prerequisite to understand underlying mechanisms of ... Polyclonal but also monoclonal allergen-specific IgG antibodies have been already described to inhibit IgE ...